Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Common Equity (2016 - 2025)

IGC Pharma (IGC) has disclosed Common Equity for 15 consecutive years, with $8.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 9.69% to $8.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.1 million, a 9.69% increase, with the full-year FY2025 number at $6.3 million, down 13.54% from a year prior.
  • Common Equity was $8.1 million for Q3 2025 at IGC Pharma, up from $6.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $32.8 million in Q1 2021 to a low of $6.1 million in Q2 2025.
  • A 5-year average of $16.3 million and a median of $14.1 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 37.27% in 2021, then crashed 50.9% in 2024.
  • IGC Pharma's Common Equity stood at $29.5 million in 2021, then tumbled by 37.86% to $18.3 million in 2022, then crashed by 50.58% to $9.1 million in 2023, then crashed by 30.86% to $6.3 million in 2024, then rose by 29.29% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Common Equity are $8.1 million (Q3 2025), $6.1 million (Q2 2025), and $6.3 million (Q1 2025).